Compare PMEC & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMEC | TVRD |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 27.5M |
| IPO Year | 2021 | 2013 |
| Metric | PMEC | TVRD |
|---|---|---|
| Price | $0.60 | $1.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | 91.8K | ★ 159.9K |
| Earning Date | 07-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $911,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 959.30 |
| 52 Week Low | $0.31 | $0.93 |
| 52 Week High | $2.44 | $43.65 |
| Indicator | PMEC | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 62.32 | 24.12 |
| Support Level | $0.51 | N/A |
| Resistance Level | $0.81 | $2.02 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 67.11 | 8.72 |
Primech Holdings Ltd is a Singapore-based facilities services and AI robotics group with operations in Singapore and Hong Kong. Through its subsidiaries, the company provides integrated facilities management, cleaning and stewarding services to the public and private sectors, serving airports, educational institutions, healthcare facilities, commercial buildings and hospitality venues. It also develops HYTRON, an autonomous restroom-cleaning robot that uses AI perception and robotic manipulation. In addition, the company operates HomeHelpy, a digital platform for booking home services for consumers.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.